HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $7 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $7 price target.
Read original at benzingaStocks · News reference
8-K filing — PDS Biotechnology Corp (PDSB)
Filed: 2026-08-11 AccNo: 0001140361-26-032142 Size: 202 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Aug 11, 2026, 12:30 PM
- Checked
- Aug 11, 2026, 12:30 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
PDS Biotechnology Intends To Cut Workforce By 36%; Removes Stephan Toutain As COO, Effective Aug. 21
SEC.
Read original at benzinga8-K filing — PDS Biotechnology Corp (PDSB)
Filed: 2026-08-25 AccNo: 0001140361-26-034320 Size: 154 KB Item 2.05: Cost Associated with Exit or Disposal Activities Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Read original at edgarPDS Biotechnology Says Lars Boesgaard To Resign As CFO, Principal Financial Officer & Principal Accounting Officer Effective Sept 12; Frank Bedu-Addo Appointed As Interim Principal Financial Officer
On August 13, 2026, Lars Boesgaard submitted his resignation, effective as of September 12, 2026, as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corporation
Read original at benzinga